Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "Complement C4 Antibody Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P <.01 for all).